- Gynecologic Cancer
  - Cervical/ vaginal
    - **9892:** Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
  - Ovarian
    - **10403:** Phase 1 Trial of Gemcitabine Combined with the BAY1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer (Dose escalation: advanced solid tumor malignancies; Expansion ovarian and pancreatic cohorts)
    - **10422:** Abemaciclib and Olaparib for Recurrent Ovarian Cancer
    - ▼ **10324:** A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
    - **10433:** Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors
    - ***10597**: A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers
    - ***10551**: Phase I/Ib Study of Anti-CD47 Magrolimab in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors (Ovarian cancer, Prostate cancer and Breast cancer)
  - Uterine
    - **10355:** A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies (Escalation: HER2 positive advanced solid tumors; Expansion: HER2 positive uterine serous carcinoma)
    - **10401:** A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma